Dr. Leigha Sharp, MD

Dr. Sharp practices at Southwest Skin and Vein Center in Buda, Texas.

Dr. Sharp's NPI, 1386091288, was assigned on May 20, 2016. Dr. Sharp graduated from Paul L. Foster School of Medicine in 2016. Dr. Sharp holds Texas license S4686.

Dr. Sharp's primary practice is Southwest Skin and Vein Center, at 211 N Fm-1626, Buda, TX 78610 in Hays County. The practice phone is (512) 444-7208.

Dr. Sharp's primary practice is Southwest Skin and Vein Center in Buda, Texas. The medical group on file is Southwest Dermatology & Vein. Dmand AI also links Dr. Sharp to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Sharp practices. Vendor and product names are available with a free account.

Dermatology is Dr. Sharp's primary specialty in the NPI Registry, under taxonomy code 207N00000X. Dr. Sharp is board certified in dermatology by the American Board of Dermatology. Dr. Sharp is licensed in Texas.

Dmand AI lists acne, acute skin infection, benign or precancerous skin growths, cancerous skin growth removal, cold sores or genital herpes, contact dermatitis, facial skin infection and hives among the conditions Dr. Sharp treats.

CMS data shows 5,352 Medicare services from Dr. Sharp across 21 procedure codes in 2024, for 849 Medicare patients. Medicare paid $244,974 for them. Every service was in an office.

CMS counts 849 Medicare patients who saw Dr. Sharp in 2024. The largest group is 65 to 74, with 419 patients. 75% of them have high cholesterol, and 64% have high blood pressure. 2% are also on Medicaid. Their average risk score is 0.93, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Sharp's median patient age at 67, with 62% women.

In 2024, Dr. Sharp wrote 1,605 Medicare Part D claims for 542 patients. 86% of them were for generic drugs. CMS names the drug for 1,445 of them, across 27 drugs with 11 or more claims each, at $825,998 in total drug cost. In 2023, CMS named 1,118 claims across 26 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 94 out of 100 for Dr. Sharp for performance year 2024, reported as part of a group. Dr. Sharp accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 1,702 procedures of removal of skin lesions by Dr. Sharp, more than 97% of the clinicians it reports for that procedure.

Removal of nail tissue: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 5 papers to Dr. Sharp, published from 2019 to 2020. 2019 was the busiest year, with 3. Dr. Sharp has published most often in Proc (Bayl Univ Med Cent). Dr. Sharp's most frequent co-authors are Cloyce L. Stetson, MD, Michelle Babb Tarbox, MD and Russell Scott Akin, MD.

CMS Open Payments shows 301 general payments to Dr. Sharp from 22 drug and device companies from 2020 to 2025. Food and beverage make up the largest share, 98% of the total. Abbvie Inc. paid the most, $896.

Dr. Sharp graduated from Paul L. Foster School of Medicine in 2016.

Dr. Sharp is in network with 20 carriers, including Aetna, United Healthcare and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 12. Check the plan with the practice before a visit.